ALKALON RAISE ANOTHER € 1.5 MILLION IN VENTURE CAPITAL

Alkalon announces that it has closed a financing round raising another DKK 11 million (€ 1.5 million) from its current investors syndicate.
This brings the total investment in the company up to DKK 25 million (€ 3.4 million) and will allow Alkalon to operate through 2010–11.

The business continually operates from the company’s head office in Copenhagen whereas most in-house R&D activities have been
moved from the laboratories of a fully owned subsidiary in Sweden to a new development laboratory in Denmark.

Chief Executive Officer Mr. Bo Tandrup said: “We have employed 3 new scientists in 2009 and with this capital injection we are in the
best possible position to meet our strategic goals on time. We are in the process of signing licensing and supply agreements with a
number of large pharmaceutical companies so we aim at having products on the market within 2 years”.

Alkalon is a privately owned Danish-Swedish pharmaceutical company engaged in formulation development, registration, and supply
of over-the-counter medicinal products to Pharma companies. Alkalon’s primary focus is launch of a portfolio of new, improved
pharmaceutical formulations which will be superior to existing products on the target markets.

For further information, please contact:

Bo Tandrup, CEO
+45 51 86 84 82
bt@alkalon.com

or visit www.alkalon.com